Tulmimetostat (CPI-0209): Mechanism of Action

Tulmimetostat (CPI-0209) MOA:Targeting EZH2/Histone Methylation Pathway for ARID1A-Mutated Gynecological Malignancies

🎯 check Tulmimetostat (CPI-0209) product page

Tulmimetostat (CPI-0209) is a potent, selective, and orally bioavailable EZH2 and EZH1 dual inhibitor. It affects PRC2-mediated epigenetic signaling, by blocking histone H3 lysine 27 (H3K27) trimethylation, inhibiting tumor cell proliferation and promoting apoptosis.

Primary Applications and Mechanism of Action